Pharmaceuticals, Biotechnology and Life Sciences
The startup company Novel Concepts Medical has announced major breakthrough in its research of COVID-19. Its novel plant-based treatment has…
The next phase of the Company’s strategy is to expand the Group’s capabilities by reinvesting proceeds from the recent sale of shares held in SkinBioTherapeutics plc, which generated approximately £2 million. These funds have provided growth capital to broaden and expand the Group’s sales and marketing team, accelerate new product development, increase marketing spend and explore direct to consumer channels in strategic markets. These funds also allow the Company to invest in acquiring new technologies to create a future pipeline of products. This supplements existing plans for expanding product ranges into sports nutrition (LeanBiome™) and healthy ageing (WellBiome®), extending SlimBiome®, OptiBiome®, and LPLDL® product lines and territories, increasing the number of larger partners, and growing gross profit by moving up the value chain to sell a greater portion of finalised products than functional ingredients.
Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH. As a result of the acquisition, Medix…
Despite the devasting impact of the COVID-19 pandemic, cardiovascular disease remains the leading killer of women in the U.S., according…
Sanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in…
Hikma Pharmaceuticals PLC has completed acquisition of the Canadian assets of Teligent Inc. for $45.75 million. The acquisition marks Hikma’s…
Pfizer said Wednesday that the results from multiple studies showed the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron.
Gilead Sciences was reported as filing a lawsuit against certain suppliers and distributors of selling fake versions of its HIV…
The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced top-line data from a Phase 1b/2 clinical trial evaluating alvelestat, a novel, orally active Neutrophil Elastase (NE) inhibitor in hospitalized COVID-19 Respiratory Disease patients.
Novavax Monday said that the European Medicines Agency (EMA) has recommended granting a conditional marketing authorization for its ‘ COVID-19 vaccine.